This has been further elicited in CT26 inoculated murine models with co-PD-L1 and TIGIT blockade, which resulted in enhanced CD8+ T cell effector responses and a 75% decrease in mean tumour volume after 16 days of treatment, significantly higher clearance compared to individual receptor targeting alone (P < 0.0001) [22]. The gene discussed is CD8A; the disease is neoplasm.